The fourth wave of "soul bargaining" comes with an average 52% price reduction for the selected drugs
◎Our reporter Zhang Jiaxing
The country's centralized procurement negotiations for drugs are vividly called "soul bargaining".
"The price cut is not like squeezing toothpaste", "This quote is unlucky", "You can make another phone call" and other bargaining phrases have made many netizens cry out. Move the price "moisture" to squeeze out, for the people to use drugs for the greatest benefit.
On February 3, the fourth batch of state-organized centralized drug procurement organized by the provinces of the country formed an alliance, and the result of the proposed selection was produced in Shanghai.
The fourth wave of "soul bargaining" is here!
What's the record?
A reporter from the Science and Technology Daily learned from the National Medical Insurance Bureau that after this centralized collection, the cost of a batch of commonly used drugs and anti-cancer drugs will be significantly reduced.
A total of 45 drugs were included in the purchase, and all were successfully purchased. The average price of the drugs to be selected was reduced by 52%.
According to reports, to implement the spirit of the General Office of the State Council "Opinions on Promoting the Normalized and Institutionalized Development of Drug Centralized and Volume Procurement", under the organization and guidance of the National Medical Insurance Bureau and other relevant departments, the fourth batch of national provinces formed an alliance to develop The organization of centralized drug procurement adheres to the basic principles of "quantity and price linkage, integration of recruitment and procurement" and the working mechanism of "national organization, alliance procurement, and platform operation".
Adhere to high-quality standards, and still pass the quality and efficacy consistency evaluation as a condition for the entry of generic drugs.
At the same time, further fine-tuning and optimizing the procurement rules, the maximum number of selected companies will be increased from the original 8 to 10, and the supply guarantee capability will be improved.
By optimizing the procurement rules, the proportion of selected companies has increased this time. Multinational companies and top 100 companies have actively participated. The selected drugs will meet the needs of patients with high quality.
Data show that a total of 152 companies participated in this centralized procurement, resulting in 118 companies to be selected, and the proportion of companies to be selected has increased to 71%.
There are 158 products to be selected, including 5 products of 5 foreign-funded companies, involving German, French, Indian and Japanese multinational pharmaceutical companies.
Among the products to be selected, the products of listed companies, foreign-funded enterprises, top 100 companies and other enterprises accounted for 62%. At the same time, there are also two original drugs such as amisulpride tablets and propofol medium/long-chain fat emulsion injections.
Among them, the schizophrenia treatment drug amisulpride was selected by Sanofi, the original research drug company, and the price of a single tablet was reduced from 12 yuan to 1.6 yuan, and patients can save about 912 yuan per month.
The fourth "soul bargaining" involved a variety of treatment areas such as hypertension, diabetes, digestive tract diseases, mental diseases, and malignant tumors, and the people benefited widely. Taking the gastric ulcer treatment drug esomeprazole enteric-coated tablets (20mg/tablet) as an example, the price of each tablet dropped from 9 yuan to 3 yuan after the collection, and the entire treatment course can save about 240 yuan. It is expected that patients across the country will use the medicines after the price reduction of this centralized procurement in May 2021.